Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.60    3.80 (2.49%)
Bid:
156.40
Ask:
156.80
Spread: 0.40 (0.256%)
Market Cap: £896.25m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM / Interim Management Statement

24 Apr 2014 07:00

ELEMENTIS PLC - AGM / Interim Management Statement

ELEMENTIS PLC - AGM / Interim Management Statement

PR Newswire

London, April 23

24 April 2014 AGM / Interim Management Statement Elementis plc (ELM.L, the "Company" or the "Group"), the Global SpecialtyChemicals Company, today issues its Interim Management Statement for the threemonths ended 31 March 2014. Commenting on the Company's performance during the quarter Group ChiefExecutive, David Dutro, said: "Elementis has started the year with good sales momentum across its broad basedgrowth platform and we anticipate full year earnings will be in line withmarket expectations. As noted at the time the Group reported its Final Results, short term weatherissues impacted our North American based coatings, oilfield and chromiumbusinesses in January and February, as snow and unusually cold temperaturesdisrupted transportation and caused some customers to temporarily close plants.Despite these impacts Specialty Products still posted solid growth with stablemargins and, although sales volumes in Chromium, the division with the highestdependency on North America, were slightly below the previous year, itsoperating profit was comfortably ahead of the comparative period. Coatings additives continued to experience strong growth in Asia Pacific andLatin America and our investment in our new North American facility in NewMartinsville continues to show good progress, delivering innovative additivesto the decorative coatings market. This contributed to our coatings business inthe region delivering an attractive growth rate. Oilfield additives had a slower, weather affected, start to the year but wecontinue to believe that the underlying market drivers of this business remainpositive, as evidenced by good growth in March. Personal care posted another successful quarter based on geographic expansionand new product launches." In Specialty Products, sales volumes in the first quarter were 3 per centhigher than the same period last year with currency having no material impacton sales or operating profit and operating margins remained stable. * In coatings additives, sales volumes in North America were 6 per cent higher than the previous year, with good growth in decorative coatings driven by the introduction of new innovative products from the recently commissioned facility in New Martinsville. Sales volumes in Latin America were 9 per cent higher as synergies from the Watercryl acquisition continued to deliver growth, albeit with some short term currency headwinds due to fluctuations in the Brazilian Real. Sales volumes in Asia Pacific were 8 per cent higher as the business continued to benefit from market share gains in China and good progress in other countries. In Europe it is pleasing to report that sales volumes grew by 2 per cent, in what continues to be a subdued economic environment. * In personal care, sales volumes were 49 per cent higher than the same period last year with good growth in Asia Pacific and Latin America, where additional resources were recently introduced, and the team continued to successfully expand the business both geographically and through new product introductions. * Sales volumes in oilfield were 18 per cent lower than the first quarter of 2013, although March volumes were ahead of the previous year. While the colder winter in North America is expected to be positive for the business in the medium term, driving increased drilling activity, the first quarter was impacted by the short term effects related to weather disruptions and customer order patterns. In Chromium, sales volumes influenced by weather issues were 3 per cent lowerthan the previous year but, with strong sales in higher margin applications,operating profit in the period was in line with management expectations. The Group's balance sheet remains in a strong position and is expected to be ina net cash position at the end of the year. Enquiries: Elementis + 44 (0) 207 408 9300David Dutro, Chief ExecutiveBrian Taylorson, Finance Director FTI Consulting + 44 (0) 207 831 3113Deborah ScottMatthew Cole
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.